In conclusion, KIF5B-NTRK1 facilitates the proliferation of lung cancer cells via the MAPK and PI3K/AKT signaling pathways, whereas entrectinib effectively inhibits this proliferative activity (Figure 5H). Here, KIF5B is linked to lung cancer.